Seaport Therapeutics has raised $225 million to advance its lead drug candidate, SPT-300, into Phase 2b testing as a potential treatment for major depressive disorder with or without anxious distress. The company also plans to further advance the capabilities of its Glyph technology platform.
Company Information
Company
Seaport Therapeutics
Location
Boston, Massachusetts, United States
About
Seaport Therapeutics is a clinical-stage biopharmaceutical company advancing the development of novel neuropsychiatric medicines in areas of high unmet patient needs. We have a proven strategy of advancing clinically validated mechanisms previously held back by limitations we overcome with our proprietary Glyph technology platform. All the therapeutic candidates in our pipeline of first and best-in-class medicines are based on the Glyph platform, which is uniquely designed to enable oral bioavailability, bypass first-pass metabolism and reduce hepatotoxicity and other side effects. We are led by an experienced team that was involved in inventing and developing KarXT and other neuropsychiatric medicines, and are guided by an extensive network of renowned scientists, clinicians and key opinion leaders.
BostonBiotechnologyTherapeuticsPharmaceuticalBiopharma